Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.5% Higher – What’s Next?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) were up 2.5% during mid-day trading on Monday . The company traded as high as $0.34 and last traded at $0.32. Approximately 48,039,653 shares were traded during trading, a decline of 32% from the average daily volume of 70,497,063 shares. The stock had previously closed at $0.31.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Wednesday, January 1st. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The stock has a market cap of $47.84 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. The company’s fifty day simple moving average is $0.25 and its two-hundred day simple moving average is $0.33. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.